- Role of New Prolonged Half-Life Clotting Factors in Hemophilia
https://www.hemophilia.org/sites/default/files/document/files/PHLBrochure.pdf - Value of Prophylaxis vs on-demand treatment: Application of a value framework in hemophilia.
https://onlinelibrary.wiley.com/doi/full/10.1111/hae.13589 - Non-factor replacement therapy for haemophilia: a current update
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125230/ - Hemophilia trials in the twenty-first century: Defining patient important outcomes.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6462740/ - Using pharmacokinetic for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6611373/ - Once-weekly prophylactic treatment vs. on-demand treatment with nonacog alfa in patients with moderately severe to severe haemophilia B.
https://onlinelibrary.wiley.com/doi/full/10.1111/hae.12878 - Pharmacokinetics, safety and efficacy of a recombinant factor IX product, trenonacog alfa in previously treated haemophilia B patients.
https://onlinelibrary.wiley.com/doi/full/10.1111/hae.13324 - Emicizumab Prophylaxis in Hemophilia A patients with Inhibitors
https://www.nejm.org/doi/full/10.1056/NEJMoa1703068 - Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999-2010: a surveillance project.
https://www.ncbi.nlm.nih.gov/pubmed/28183693 - Effects of a 6-week, Individualized, Supervised Exercise Program for People with Bleeding Disorders and Hemophilic Arthritis.
https://academic.oup.com/ptj/article/90/4/509/2888228 - Inhibitors of propagation of coagulation (factors VIII, IX, and XI): a review of current therapeutic practice
https://www.ncbi.nlm.nih.gov/pubmed/21204915 - Acquired Factor VIII Inhibitors: Pathophysiology and Treatment
https://ashpublications.org/hematology/article-lookup/doi/10.1182/asheducation-2006.1.432 - Optimal management of hemophilic arthropathy and hematomas
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4207585/
